ZA939317B - Medicament - Google Patents

Medicament

Info

Publication number
ZA939317B
ZA939317B ZA939317A ZA939317A ZA939317B ZA 939317 B ZA939317 B ZA 939317B ZA 939317 A ZA939317 A ZA 939317A ZA 939317 A ZA939317 A ZA 939317A ZA 939317 B ZA939317 B ZA 939317B
Authority
ZA
South Africa
Prior art keywords
medicament
Prior art date
Application number
ZA939317A
Other languages
English (en)
Inventor
Thomas Henry Brown
David Gwyn Cooper
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of ZA939317B publication Critical patent/ZA939317B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Addiction (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ZA939317A 1992-12-15 1993-12-13 Medicament ZA939317B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB929226111A GB9226111D0 (en) 1992-12-15 1992-12-15 Madicaments

Publications (1)

Publication Number Publication Date
ZA939317B true ZA939317B (en) 1995-06-13

Family

ID=10726633

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA939317A ZA939317B (en) 1992-12-15 1993-12-13 Medicament

Country Status (8)

Country Link
EP (1) EP0674514A1 (xx)
JP (1) JPH08504419A (xx)
CN (1) CN1091636A (xx)
AU (1) AU5698394A (xx)
GB (1) GB9226111D0 (xx)
MX (1) MX9307946A (xx)
WO (1) WO1994013291A1 (xx)
ZA (1) ZA939317B (xx)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9314973D0 (en) * 1993-07-20 1993-09-01 Smithkline Beecham Plc Medicaments
GB9411052D0 (en) * 1994-06-02 1994-07-20 Smithkline Beecham Plc Medicaments
GB9411045D0 (en) * 1994-06-02 1994-07-20 Smithkline Beecham Plc Compounds and use
AU2982595A (en) * 1994-07-14 1996-02-16 Smithkline Beecham Plc Benzocycloalkylamine derivatives as calcium chanel antagonists
US5794887A (en) 1995-11-17 1998-08-18 Komerath; Narayanan M. Stagnation point vortex controller
AU713236B2 (en) * 1996-02-15 1999-11-25 Sankyo Company Limited Diarly alkane derivatives containing an alicyclic group, their preparation and their theraputic and prophylactic uses
CA2232147A1 (en) * 1997-04-03 1998-10-03 F. Hoffmann-La Roche Ag Phenoxymethyl piperidine derivatives
US6110937A (en) 1997-04-03 2000-08-29 Syntex Usa, Inc. Phenoxymethyl piperidine derivatives for the treatment of neuropathic pain
AU1600599A (en) 1998-02-27 1999-09-15 Warner-Lambert Company Heterocyclic substituted aniline calcium channel blockers
US6166052A (en) 1998-03-11 2000-12-26 Warner-Lambert Company Heteroaryl alkyl alpha substituted peptidylamine calcium channel blockers
US7652017B2 (en) 1999-12-21 2010-01-26 Mitsubishi Tanabe Pharma Corporation Remedies and/or preventives for nervous system disorders
US7294637B2 (en) 2000-09-11 2007-11-13 Sepracor, Inc. Method of treating addiction or dependence using a ligand for a monamine receptor or transporter
AU9087301A (en) 2000-09-11 2002-03-26 Sepracor Inc Ligands for monoamine receptors and transporters, and methods of use thereof
BRPI0408136A (pt) 2003-03-07 2006-03-01 Astellas Pharma Inc derivados heterocìclicos contendo nitrogênio tendo estirila 2,6-dissubstituìda
EP1735302B1 (en) 2004-02-27 2010-06-16 Eli Lilly And Company 4-amino-piperidine derivatives as monoamine uptake inhibitors
US7417040B2 (en) 2004-03-01 2008-08-26 Bristol-Myers Squibb Company Fused tricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3
WO2007040682A1 (en) * 2005-09-21 2007-04-12 Decode Genetics Ehf. Biaryl substituted heterocycle inhibitors of lta4h for treating inflammation
EP1963261A1 (en) * 2005-12-21 2008-09-03 Decode Genetics EHF Biaryl substituted nitrogen containing heterocycle inhibitors of lta4h for treating inflammation
CN107846898B (zh) * 2015-05-01 2023-07-14 佐治亚州立大学研究基金会 用于管理低氧诱导因子相关病症的二苯基甲醇衍生物

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1096441A (en) * 1964-01-15 1967-12-29 Bristol Myers Co Ethers of benzyl phenols and a process for the preparation thereof
US3360526A (en) * 1964-01-15 1967-12-26 Bristol Myers Co Heterocyclicamino methylene ethers of benzylphenols
GB1203149A (en) * 1968-06-10 1970-08-26 Ici Ltd Piperidine derivatives
GB1319252A (en) * 1969-06-05 1973-06-06 Ciba Geigy Ag 1-phenyl-alkanols and process for making same
DE2728898A1 (de) * 1977-06-27 1979-01-18 Thomae Gmbh Dr K Neue morpholinderivate
DE2811952A1 (de) * 1978-03-18 1979-10-31 Merck Patent Gmbh Phenoxyalkylamine und verfahren zu ihrer herstellung
FR2443246A1 (fr) * 1978-12-05 1980-07-04 Pharmindustrie Nouveaux medicaments a base de derives de la phenyl-1 (piperidyl-4)-3 propanone-1
IE66332B1 (en) * 1986-11-03 1995-12-27 Novo Nordisk As Piperidine compounds and their preparation and use
DK231088D0 (da) * 1988-04-28 1988-04-28 Ferrosan As Piperidinforbindelser, deres fremstilling og anvendelse
US4822778A (en) * 1988-01-19 1989-04-18 Gunnar Aberg Membrane stabilizing phenoxy-piperidine compounds and pharmaceutical compositions employing such compounds
US5169855A (en) * 1990-03-28 1992-12-08 Du Pont Merck Pharmaceutical Company Piperidine ether derivatives as psychotropic drugs or plant fungicides
MX9100513A (es) * 1990-08-06 1992-04-01 Smith Kline French Lab Compuestos
MX9100517A (es) * 1990-08-06 1992-04-01 Smith Kline French Lab Compuestos
GB9113031D0 (en) * 1991-06-17 1991-08-07 Smithkline Beecham Plc Compounds
EP0629190A1 (en) * 1992-01-28 1994-12-21 Smithkline Beecham Plc Compounds as calcium channel antagonists

Also Published As

Publication number Publication date
CN1091636A (zh) 1994-09-07
WO1994013291A1 (en) 1994-06-23
MX9307946A (es) 1994-08-31
JPH08504419A (ja) 1996-05-14
EP0674514A1 (en) 1995-10-04
AU5698394A (en) 1994-07-04
GB9226111D0 (en) 1993-02-10

Similar Documents

Publication Publication Date Title
GB9202519D0 (en) Medicaments
IL103303A0 (en) Medicament
GB9201749D0 (en) Medicaments
ZA939317B (en) Medicament
GB9216380D0 (en) Medicaments
HU9300804D0 (en) Pharmaceutical preparatives
AP9300547A0 (en) Syringe
GB9121463D0 (en) Medicament
ZA938832B (en) Medicaments
GB9202522D0 (en) Medicaments
GB9204767D0 (en) Medicament
GB9214905D0 (en) Medicament
GB9201750D0 (en) Medicaments
GB9225684D0 (en) Medicaments
GB9210306D0 (en) Medicaments
GB9211802D0 (en) Medicaments
GB9211803D0 (en) Medicaments
GB9213788D0 (en) Medicaments
GB9215749D0 (en) Medicaments
GB9206083D0 (en) Medicaments
GB9216381D0 (en) Medicaments
GB9201404D0 (en) Medicaments
GB9205980D0 (en) Medicaments
GB9219301D0 (en) Medicaments
GB9219318D0 (en) Medicaments